Hamilton Thorne Announces Annual and Special Meeting Voting Results

Hamilton Thorne Ltd.

BEVERLY, Mass. and TORONTO, June 15, 2022 (GLOBE NEWSWIRE) — Hamilton Thorne Ltd. (TSX-V: HTL) (“Hamilton Thorne“or the”Company”), a leading supplier of precision instruments, consumables, software and services to the assisted reproductive technology (ART), research and cell biology markets, is pleased to announce that the all of the resolutions proposed at its annual and extraordinary general meeting of shareholders held on June 14, 2022 (the “Meeting“) were duly adopted.

At the meeting, David Wolf, Karen Firestone, Feng Han, Bruno Maruzzo, Robert J. Potter, Marc H. Robinson, David B. Sable and Daniel K. Thorne were elected directors of the Company to serve until at the conclusion of the next annual general meeting of the Company or until their successors are elected or appointed. MNP LLP has also been reappointed as auditors of the Company until the close of the next annual and general meeting of shareholders or until their successors are appointed, and the directors of the Company have been authorized to fix the remuneration of auditors for the current year. in such amounts as the directors may, in their discretion, determine.

In addition to the usual corporate matters approved at the Meeting, the shareholders of the Company also: (i) approved the consolidation of the issued and outstanding common shares of the Company (“Ordinary actions”) to such consolidation ratio to be determined by the directors of the Company at their sole discretion; (ii) approved and ratified an amendment to the Company’s 2019 Long-Term Equity Incentive Plan (the “2019 stock incentive plan”) to increase the maximum number of common shares issuable under the 2019 Stock Incentive Plan by 5,000,000 common shares, from 6,000,000 common shares to 11,000,000 common shares. ordinary shares (the “Increase”); and (iii) approved and ratified the grant of 744,877 restricted stock units (“USR”) issued on April 12, 2022 to certain officers, directors and key employees of the Company.

In addition to the Increase, shareholders of the Company approved the following administrative changes to the 2019 Stock Incentive Plan: (i) the removal of the feature that provided that stock options exercised become available to be reallocated; (ii) clarify that certain adjustments made pursuant to the 2019 Long-Term Equity Incentive Plan will be subject to prior acceptance by the TSX Venture Exchange; (iii) clarify the circumstances under which the expiration time of stock options may be extended during a blackout period; (iv) set limits on when RSUs may vest; and (v) remove references to certain amendments to the 2019 Stock Incentive Plan that would not require shareholder approval, all as more fully described in the Company’s management information circular dated May 10, 2022, available on the Company’s profile at www.sedar.com.

About Hamilton Thorne Ltd. (www.hamiltonthorne.ltd)

Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce costs, increase productivity, improve outcomes and enable breakthroughs in assisted reproductive technology (ART) markets ), research and cell biology. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, Tek-Event, IVFtech and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, academic research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research institutions.

Neither the Toronto Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain information contained in this press release may contain forward-looking statements. This information is based on current expectations which are subject to significant risks and uncertainties that are difficult to predict. Actual results may differ materially from the results suggested in the forward-looking statements. The Company undertakes no obligation to update any forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements, except if and until securities laws applicable to the Company so require. Additional information identifying the risks and uncertainties is contained in the documents filed by the Company with the Canadian securities authorities, which documents are available on www.sedar.com.

For more information please contact:

David Wolf, President and CEO
Hamilton Thorne Ltd.
978-921-2050
[email protected]

Michel Bruns, Chief Financial Officer
Hamilton Thorne Ltd.
978-921-2050
[email protected]

Glen Akselrod
Bristol Investor Relations
905-326-1888
[email protected]

Comments are closed.